RIO DE JANEIRO, BRAZIL - The vaccine against Covid-19 from the Chinese manufacturer Sinovac is safe and is able to produce an immune response in the body 28 days after its administration in 97 percent of cases, according to a peer-reviewed article published on Tuesday, November 17th in the Lancet Infectious Diseases scientific journal.
The results are the based on the analysis of phase 1 and 2 clinical trials conducted in China in April and May with 744 healthy volunteers aged 18 to 59 and with no history of Sars-CoV-2 coronavirus infection.
Although the Coronavac vaccine is . . .